ALK CEO on peanut allergy competitors: "They might have been the first, but that does not necessarily mean they are the best"
In 2022, allergy group ALK is initiating a peanut allergy market effort, an area that the companies Aimmune and DBV Technologies have long been targeting. Their results have been less prominent, and all they’re doing is opening the door for more threatening competition, says President and CEO at ALK Carsten Hellmann.
BY ALBERT RØNNING-ANDERSSON, TRANSLATED BY DANIEL PEDERSEN
It created a buzz when the allergy group ALK announced in February that it would initiate a massive venture within food allergy, which is a massive market, far bigger than that ALK’s well-trodden territory of respiratory allergies.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
ALK upgrades guidance after positive Q3 report
For subscribers
Global supply issues have ALK thinking creatively
For subscribers
